RxLegal: Pharmacist Gag Clauses

Area of Science:

• Health Policy
• Pharmacy Practice
• Health Economics

Background:

• Contracts between insurance companies/pharmacy benefit managers (PBMs) and pharmacies often include gag clauses.
• These clauses restrict pharmacists from informing patients about lower direct cash prices for medications compared to insurance prices.

Purpose of the Study:

• To examine the implications of gag clauses in pharmacy contracts.
• To highlight the impact of these clauses on medication transparency and patient affordability.

Main Methods:

• Analysis of contract clauses and their impact on patient information dissemination.
• Review of criticisms regarding the effect of gag clauses on PBMs' drug pricing negotiations.

Main Results:

• Gag clauses conceal the most cost-effective purchasing options for prescription drugs.
• Critics argue this practice reduces medication affordability and contradicts PBMs' role in negotiating drug prices.

Conclusions:

• Gag clauses hinder transparency in prescription drug pricing.
• Legislative efforts, such as the Patient Right to Know Drug Prices Act, aim to ban this practice to improve patient access to cost-saving information.